AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30213052
Drug: Half-A (68
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Half-A (68 g fresh Hass avocado)
Trial: 30213052
Drug: Whole-A (136
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole-A (136 g fresh Hass avocado)
Trial: 30213052
Drug: Control (0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (0 g avocado)
Trial: 22323869
Drug: Oral solubilized
RxNorm normalized name: VITAMIN A PALMITATE (SOLUBILIZED)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral solubilized UDCA (3.5 g/140 mL/day)
Trial: 15857210
Drug: Ganopoly (polysaccharide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ganopoly (polysaccharide extract of G. lucidum)
Trial: 30114980
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and commitment therapy model in occupational rehabilitation programme
Trial: 24781718
Drug: Control (no
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (no anti-adhesion treatment)
Trial: 23097096
Drug: Hydrocortisone (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (100 mg) administered intravenously in three doses, eight hours apart
Trial: 3415889
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine 20 ml h‐1 (in saline)
Trial: 42224
Drug: mepindolol-sulfate (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mepindolol-sulfate (2 x 2.5 mg)
Trial: 31787433
Drug: Heparin-coated (HC)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heparin-coated (HC) circuits
Trial: 31445354
Drug: Necitumumab (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Necitumumab (800 mg) with nab-paclitaxel (100 mg/m2) and carboplatin (AUC 6 mg*min/mL) for 4 cycles, followed by necitumumab and nab-paclitaxel maintenance
Trial: 29234057
Drug: Carnosine supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carnosine supplementation (2g daily for 12 weeks)
Trial: 23401618
Drug: E2 administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 administration during the last 7 days of GnRHant
Trial: 23401618
Drug: E2 administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E2 administration
Trial: 15955900
Drug: Lapatinib (GW572016)
DrugBank: Lapatinib (DB01259)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Lapatinib (GW572016) administered once daily at doses ranging from 500 to 1,600 mg
Trial: 11449341
Drug: Enoxaparin, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin, 40 mg once daily for 6 to 14 days
Trial: 9249964
Drug: Functional use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional use of 'blue' and 'yellow' groups assigned on the basis of a biological attribute
Trial: 7951125
Drug: Ciprofloxacin 500
RxNorm normalized name: ciprofloxacin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 500 mg orally twice a day plus antifungal prophylaxis (fluconazole 50 mg once daily plus amphotericin B 200 mg four times a day) and streptococcal prophylaxis for 10 days after BMT
Trial: 31402293
Drug: 50,000 units
RxNorm normalized name: Kovia 6.5, 650,000 units/g-10% topical ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50,000 units VitD3 capsules every week for 7 weeks
Trial: 31402293
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 300,000 units VitD3 ampoule
Trial: 31402293
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of half of the injection dose followed by oral capsule for 4 weeks
Trial: 28597922
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg DFN-02
Trial: 28597922
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg DFN-02
Trial: 28597922
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg DFN-02
Trial: 28597922
Drug: 6 mg
RxNorm normalized name: boron 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 mg subcutaneous sumatriptan injection
Trial: 25204557
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg oral lenvatinib (5 mg for severe hepatic impairment)
Trial: 22068930
Drug: sports-cADHD (90-min
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sports-cADHD (90-min athletic activity, twice a week for 6 weeks)
Trial: 21059176
Drug: Dapoxetine (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dapoxetine (both doses)
Trial: 10429599
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard treatment without reorientation measures)
Trial: 6457152
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg of the alpha-blocker thymoxamine given by inhalation
Trial: 22677643
Drug: Topical pranoprofen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical pranoprofen 0.1% plus topical sodium hyaluronate 0.1%
Trial: 20461969
Drug: Montelukast (MK)
DrugBank: Montelukast (DB00471)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Montelukast (MK) 10 mg/d
Trial: 18657569
Drug: School-based drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: School-based drug abuse prevention program (12-hour class-based curriculum)
Trial: 15709845
Drug: Pharmacotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy with clinical management
Trial: 7547089
Drug: Tenidap sodium
RxNorm normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap sodium (120 mg day-1)
Trial: 7547089
Drug: Tenidap sodium
RxNorm normalized name: tenidap sodium
DrugBank: Tenidap (DB13481)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tenidap sodium (single dose)
Trial: 2326032
Drug: Low-dose ketamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose ketamine with diazepam, meperidine, and nitrous oxide
Trial: 27909031
Drug: Topical gel
RxNorm normalized name: Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical gel from flax seed oil
Trial: 24467781
Drug: 8‐week group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8‐week group Cognitive Behavioural Therapy (CBT) treatment
Trial: 24467781
Drug: Waitlist (8‐week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waitlist (8‐week clinical monitoring preceding treatment)
Trial: 22198452
Drug: Tetrabenazine (TBZ)
RxNorm normalized name: Tetrabenazine
DrugBank: Tetrabenazine (DB04844)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tetrabenazine (TBZ) 12.5-75 mg/d, titrated according to a fixed, flexible schedule
Trial: 20633266
Drug: Capsimax (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capsimax (2 mg capsaicinoids in a microencapsulated matrix)
Trial: 30699151
Drug: Intravenous amphotericin
RxNorm normalized name: amphotericin
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous amphotericin B 1mg/kg for 2 weeks and oral Fluconazole 800mg daily for 10 weeks
Trial: 29288137
Drug: Men choosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Men choosing treatment
Trial: 25801892
Drug: Intensive regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive regimen (IR) of cholecalciferol (300.000 UI at baseline and 50.000 UI/monthly)
Trial: 25801892
Drug: Standard regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard regimen (SR) of cholecalciferol (25.000 UI monthly)
Trial: 23719555
Drug: Low serum
RxNorm normalized name: ZINC OXIDE 20 g in 100 mL TOPICAL CREAM [Sunceutical SPF 50 Mineral Glow Serum]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low serum vitamin K1 in antihypertension medication users
Trial: 16600506
Drug: Naloxone hydrochloride
RxNorm normalized name: Naloxone Hydrochloride
DrugBank: Naloxone (DB01183)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Naloxone hydrochloride (0.14 mg/kg)
Trial: 10808170
Drug: MF DPI
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MF DPI 50 microg twice daily
Trial: 10808170
Drug: MF DPI
RxNorm normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: MF DPI 100 microg twice daily
Trial: 9228350
Drug: Inhaled salbutamol
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Inhaled salbutamol for 6 weeks, increased in stepwise fashion at 2-week intervals
Trial: 8497871
Drug: Ketoconazole (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketoconazole (200 mg/day) with reduced cyclosporine doses
Trial: 8497871
Drug: Standard doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard doses of cyclosporine
Trial: 8497871
Drug: Reduced doses
RxNorm normalized name: Iron, reduced
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Reduced doses of cyclosporine with ketoconazole
Trial: 3027838
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg itraconazole twice a day for five days
Trial: 3027838
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg itraconazole once a day for five days
Trial: 23907764
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg oral cortisol
Trial: 23907764
Drug: Both insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both insulin and cortisol
Trial: 22272611
Drug: MK-0249 5-mg
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MK-0249 5-mg daily for 4 weeks
Trial: 20369760
Drug: Group M:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group M: 2 ml of 0.5% hyperbaric bupivacaine plus morphine 100 microg plus fentanyl 15 microg, mixed in a syringe
Trial: 20369760
Drug: Group S:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group S: 2 ml of 0.5% bupivacaine followed by morphine 100 microg plus fentanyl 15 microg through a separate syringe
Trial: 18662943
Drug: Switch to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Switch to a combination of emtricitabine, didanosine and efavirenz for 48 weeks
Trial: 15728401
Drug: ACE inhibitors
RxNorm normalized name: ACE INHIBITORS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ACE inhibitors (n = 26, 1-2 mg/day temocapril or trandolapril)
Trial: 15728401
Drug: Calcium-channel blockers
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-channel blockers (CCB, n = 23, 2.5-5 mg/day amlodipine)
Trial: 12499343
Drug: Cholecalciferol 25
RxNorm normalized name: cholecalciferol 250 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 25 micro g/d
Trial: 12499343
Drug: Cholecalciferol 125
RxNorm normalized name: cholecalciferol 125 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 125 micro g/d
Trial: 12499343
Drug: Cholecalciferol 250
RxNorm normalized name: cholecalciferol 250 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 250 micro g/d
Trial: 12499343
Drug: Cholecalciferol 0
RxNorm normalized name: cholecalciferol 0.1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholecalciferol 0 micro g/d (control)
Trial: 12499343
Drug: Total input
RxNorm normalized name: Colgate Total Mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total input from all sources (supplement, food, tissue stores)
Trial: 8838194
Drug: Oral acyclovir
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral acyclovir (800 mg five times daily)
Trial: 1497518
Drug: Subconjunctival injections
RxNorm normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subconjunctival injections of fluorouracil (4 to 6 injections for 10 days after surgery)
Trial: 1497518
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no fluorouracil injections)
Trial: 1497518
Drug: Subconjunctival injections
RxNorm normalized name: lincomycin
DrugBank: Lincomycin (DB01627)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subconjunctival injections of fluorouracil
Trial: 30303695
Drug: Alpha-lipoic acid
RxNorm normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alpha-lipoic acid (ALA) 100 mg per day for 8 weeks
Trial: 30303695
Drug: Placebo (cellulose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (cellulose acetate 100 mg per day for 8 weeks)
Trial: 22951801
Drug: Psychotherapy program
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychotherapy program for treatment of co-dependence
Trial: 19383224
Drug: Pre-operative oral
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pre-operative oral administration of magnesium for 10 days
Trial: 19383224
Drug: Intra-operative flush
RxNorm normalized name: T8 Keto Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative flush infusion of magnesium
Trial: 17449998
Drug: Usual PMG
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual PMG treatment
Trial: 15223903
Drug: Immunoglobulin doses
RxNorm normalized name: immunoglobulin A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunoglobulin doses (four doses compared)
Trial: 9619936
Drug: Ambulatory chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ambulatory chemotherapy
Trial: 12652055
Drug: Weekly folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weekly folic acid supplement (2,800 microg)
Trial: 12652055
Drug: Daily folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily folic acid supplement (400 microg)
Trial: 11101478
Drug: Polydextrose 12
RxNorm normalized name: fructooligosaccharides/polydextrose 12 gram/30 mL ORAL LIQUID IN PACKET (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Polydextrose 12 g plus 50 g glucose
Trial: 31331572
Drug: Achillea wilhelmsii
RxNorm normalized name: Achillea millefolium oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achillea wilhelmsii capsules, twice daily for 4 weeks
Trial: 31331572
Drug: Achillea wilhelmsii
RxNorm normalized name: Achillea millefolium oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Achillea wilhelmsii capsules
Trial: 28434633
Drug: Testosterone propionate
RxNorm normalized name: Testosterone Propionate
DrugBank: Testosterone propionate (DB01420)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone propionate 1% ointment twice a day for 30 days
Trial: 20634190
Drug: IVIG 500
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IVIG 500 mg/kg
Trial: 16651205
Drug: Testim 1%
RxNorm normalized name: Testim 1% Topical Gel
DrugBank: Testosterone (DB00624)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testim 1% (5 g)
Trial: 16651205
Drug: AndroGel 1%
RxNorm normalized name: Androgel 1% Transdermal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AndroGel 1% (5 g)
Trial: 8541168
Drug: Encainide or
RxNorm normalized name: encainide Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Encainide or flecainide treatment
Trial: 25533774
Drug: Losartan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Losartan (100 mg per day)
Trial: 17053058
Drug: Low-power laser
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-power laser therapy (LPLT)
Trial: 16170158
Drug: Dexamethasone (DEXA)
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone (DEXA) 8 mg/m2 during induction and DEXA 6 mg/m2 during the intensifications
Trial: 16170158
Drug: Prednisolone (PRED)
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisolone (PRED) 60 mg/m2 during induction and PRED 40 mg/m2 during four intensifications in the SR group and three intensifications in the IR group
Trial: 11991446
Drug: Alendronate 80
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 80 mg
Trial: 11991446
Drug: Alendronate 160
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate 160 mg
Trial: 9473831
Drug: Dexamethasone 10
RxNorm normalized name: dexamethasone 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 10 mg preoperative dose
Trial: 354746
Drug: Co-trimoxazole (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Co-trimoxazole (single dose, intravenous infusion)
Trial: 29273261
Drug: Weekly irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly irinotecan at 95 mg/m2 for ∗1∗1 genotype
Trial: 29273261
Drug: Weekly irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly irinotecan at 80 mg/m2 for ∗1∗28 genotype
Trial: 29273261
Drug: Weekly irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly irinotecan at 80 mg/m2 for ∗1∗1 genotype
Trial: 29273261
Drug: Weekly irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly irinotecan at 65 mg/m2 for ∗1∗28 genotype
Trial: 29273261
Drug: Weekly irinotecan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly irinotecan at 80 mg/m2 and 65 mg/m2
Trial: 29273261
Drug: Capecitabine at
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine at 625 mg/m2
Trial: 26630417
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (CV)
Trial: 1702012
Drug: Ondansetron (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (8 mg tds orally)
Trial: 1702012
Drug: Metoclopramide (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoclopramide (10 mg tds orally)
Trial: 347876
Drug: Bromperidol (14-23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromperidol (14-23 mg/day during acute treatment, average maintenance dose approximately 8 mg, total doses from 3-39 mg for up to four months)
Trial: 347876
Drug: Bromperidol (acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromperidol (acute treatment)
Trial: 16455426
Drug: Low-dose anthracycline
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose anthracycline (doxorubicin 50-125 mg/m2)
Trial: 11505129
Drug: Rapid fat
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid fat infusion (0.4 x resting energy expenditure over 6 hrs)
Trial: 11505129
Drug: Slow fat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow fat infusion (0.4 x resting energy expenditure over 24 hrs)
Trial: 9250846
Drug: Enoxaparin (low-molecular-weight
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (low-molecular-weight heparin) 1 mg/kg body weight, subcutaneously twice daily for 48 hours to 8 days
Trial: 9250846
Drug: Unfractionated heparin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin, continuous intravenous administration for 48 hours to 8 days
Trial: 7685749
Drug: MOPP chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP chemotherapy followed by high-dose (40 Gy) total or subtotal nodal irradiation
Trial: 7685749
Drug: MOPP/ABVD chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP/ABVD chemotherapy followed by high-dose (40 Gy) total or subtotal nodal irradiation
Trial: 3494461
Drug: Cimetidine (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine (24 mg/kg/day) for 4 days
Trial: 31888928
Drug: NOAC-based treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NOAC-based treatment strategy
Trial: 28682187
Drug: Loss-framed message
RxNorm normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loss-framed message emphasizing consequence of not receiving flu vaccine
Trial: 28682187
Drug: Loss-framed message
RxNorm normalized name: semaglutide
DrugBank: Semaglutide (DB13928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Loss-framed message emphasizing consequence of receiving flu vaccine
Trial: 26138866
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg retosiban
Trial: 26138866
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg retosiban
Trial: 23828160
Drug: Olanzapine/Reboxetine (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine/Reboxetine (4 mg BID)
Trial: 18304693
Drug: Nesiritide plus
RxNorm normalized name: nesiritide
DrugBank: Nesiritide (DB04899)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nesiritide plus protocol-specified standard therapy
Trial: 16565626
Drug: Chan‐Chuang qi‐gong
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chan‐Chuang qi‐gong therapy for 21 days
Trial: 15194373
Drug: No-antibody induction
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-antibody induction